276 related articles for article (PubMed ID: 31145505)
1. Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates.
Chong CY; Ong RY; Seah VX; Tan NW; Chan MY; Soh SY; Ong C; Lim AS; Thoon KC
J Paediatr Child Health; 2020 Jan; 56(1):123-129. PubMed ID: 31145505
[TBL] [Abstract][Full Text] [Related]
2. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
[No Abstract] [Full Text] [Related]
3. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211
[TBL] [Abstract][Full Text] [Related]
5. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study.
Savarese I; Yazami S; De Rose DU; Carkeek K; Campi F; Auriti C; Danhaive O; Piersigilli F
J Hosp Infect; 2024 Jan; 143():76-81. PubMed ID: 37972710
[TBL] [Abstract][Full Text] [Related]
6. Central venous catheter-associated bloodstream infections in pediatric hematology-oncology patients and effectiveness of antimicrobial lock therapy.
Tsai HC; Huang LM; Chang LY; Lee PI; Chen JM; Shao PL; Hsueh PR; Sheng WH; Chang YC; Lu CY
J Microbiol Immunol Infect; 2015 Dec; 48(6):639-46. PubMed ID: 25311403
[TBL] [Abstract][Full Text] [Related]
7. Peripherally inserted central catheters are associated with lower risk of bloodstream infection compared with central venous catheters in paediatric intensive care patients: a propensity-adjusted analysis.
Yamaguchi RS; Noritomi DT; Degaspare NV; Muñoz GOC; Porto APM; Costa SF; Ranzani OT
Intensive Care Med; 2017 Aug; 43(8):1097-1104. PubMed ID: 28584925
[TBL] [Abstract][Full Text] [Related]
8. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
Chu HP; Brind J; Tomar R; Hill S
J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973
[TBL] [Abstract][Full Text] [Related]
9. The effect of the multimodal intervention including an automatic notification of catheter days on reducing central line-related bloodstream infection: a retrospective, observational, quasi-experimental study.
Bae S; Kim Y; Chang HH; Kim S; Kim HJ; Jeon H; Cho J; Lee J; Chae H; Han G; Kim SW
BMC Infect Dis; 2022 Jul; 22(1):604. PubMed ID: 35804323
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U
J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Infectious and Noninfectious Catheter Complications in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Meta-Analysis.
Reitzel RA; Rosenblatt J; Chaftari AM; Raad II
JPEN J Parenter Enteral Nutr; 2019 Sep; 43(7):832-851. PubMed ID: 31172542
[TBL] [Abstract][Full Text] [Related]
12. Asymptomatic central line-associated bloodstream infections in children implanted with long term indwelling central venous catheters in a teaching hospital, Sri Lanka.
Jayaweera JAAS; Sivakumar D
BMC Infect Dis; 2020 Jun; 20(1):457. PubMed ID: 32600427
[TBL] [Abstract][Full Text] [Related]
13. Management of enterococcal central line-associated bloodstream infections in patients with cancer.
Awadh H; Chaftari AM; Khalil M; Fares J; Jiang Y; Deeba R; Ali S; Hachem R; Raad II
BMC Infect Dis; 2021 Jul; 21(1):643. PubMed ID: 34225651
[TBL] [Abstract][Full Text] [Related]
14. The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients.
van Roeden S; van Oevelen M; Abrahams AC; Dekker FW; Rotmans JI; Meijvis SCA;
BMC Nephrol; 2021 Sep; 22(1):308. PubMed ID: 34517829
[TBL] [Abstract][Full Text] [Related]
15. Impact of a Best Practice Prevention Bundle on Central Line-associated Bloodstream Infection (CLABSI) Rates and Outcomes in Pediatric Hematology, Oncology, and Hematopoietic Cell Transplantation Patients in Inpatient and Ambulatory Settings.
Ardura MI; Bibart MJ; Mayer LC; Guinipero T; Stanek J; Olshefski RS; Auletta JJ
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e64-e72. PubMed ID: 32960848
[TBL] [Abstract][Full Text] [Related]
16. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.
van den Bosch CH; Jeremiasse B; van der Bruggen JT; Frakking FNJ; Loeffen YGT; van de Ven CP; van der Steeg AFW; Fiocco MF; van de Wetering MD; Wijnen MHWA
J Hosp Infect; 2022 May; 123():143-155. PubMed ID: 34767871
[TBL] [Abstract][Full Text] [Related]
18. CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients.
van den Bosch CH; Loeffen Y; van der Steeg AFW; van der Bruggen JT; Frakking FNJ; Fiocco M; van de Ven CP; Wijnen MHWA; van de Wetering MD
BMJ Open; 2023 Mar; 13(3):e069760. PubMed ID: 36944461
[TBL] [Abstract][Full Text] [Related]
19. Duration of central venous catheter placement and central line-associated bloodstream infections after the adoption of prevention bundles: a two-year retrospective study.
Pitiriga V; Bakalis J; Kampos E; Kanellopoulos P; Saroglou G; Tsakris A
Antimicrob Resist Infect Control; 2022 Jul; 11(1):96. PubMed ID: 35841083
[TBL] [Abstract][Full Text] [Related]
20. Lower risk of bloodstream infections for peripherally inserted central catheters compared to central venous catheters in critically ill patients.
Pitiriga V; Bakalis J; Theodoridou K; Kanellopoulos P; Saroglou G; Tsakris A
Antimicrob Resist Infect Control; 2022 Nov; 11(1):137. PubMed ID: 36352414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
